FARO ECONÓMICOSTOCK ANALYSIS

REGN — analysis and forecast

$961.26+3.6% todayRegeneron Pharmaceuticals, Inc.
Verdict
Strongly bullish
RSI (14)
88
MACD
▲ rising
Trend
Uptrend
Volatility
36%
52w range
100%

🧬 Faro multibagger DNA

Does it look today like the big multibaggers (×10, ×100) did when they started? 7 traits measured with public data.

63/ 100
Promising

Strongest: Balance sheet and Price vs. growth. Most lacking: Room to grow and Cash it generates.

Room to grow35

Worth $99.4 B. To grow ×10 it would have to reach $994 B.

Sales engine60

Sales +36% last quarter (year over year) and +1% last fiscal year · accelerating.

Business quality71

Gross margin 47%, operating margin 40%, return on equity 15%.

Cash it generates59

Free cash flow $2.6 B a year = 2.6% of its value.

Price vs. growth75

Trades at 5.9× sales: 0.32 per point of growth (lower is better).

Balance sheet93

Net cash equal to 7% of its value.

Faro seal65

Government contracts with firm money = 0.3% of its value · inside a Faro megatrend · insiders own 2.1%.

⏱️ Timing (not scored): near its 12-month high · above its 200-day average · beating the S&P 500 by 34 points over 12 months.

Built on the traits of 365 stocks that went ×100 (Mayer, 1962–2014) and 464 that went ×10 (Yartseva, 2009–2024), plus the Faro thesis. It does not predict the price and is not a recommendation. How it works and the ranking →

🔢 What the numbers say

The last 12 months, in plain words

🗓️ Forecast by horizon

Directional bias · probability of rising · expected price and likely range (68%)

HorizonBiasProb. upExpected price68% range
1 dayStrongly bullish63%$961.55 +0.0%$940.04 – $983.54
3 daysStrongly bullish63%$962.12 +0.1%$925.16 – $1,000.56
1 weekStrongly bullish64%$962.69 +0.1%$915.21 – $1,012.63
15 daysStrongly bullish65%$964.12 +0.3%$897.57 – $1,035.60
1 monthStrongly bullish65%$967.27 +0.6%$872.04 – $1,072.91
3 monthsStrongly bullish65%$979.42 +1.9%$818.47 – $1,172.01

Recent momentum: +32.3% over 20 days · +22.6% over 60 days. The further out the horizon, the wider and more uncertain the forecast.

📈 Probability cone

📜 REGN government contracts

The public money behind this company — the "Follow the Contract" pattern.

Health & Human Services$278 M
Modification · official · Sep 25, 2026

Inmazeb ebola therapeutics

💡 Worth 0.28% of the company's market value. Firm money at signing: $278 M. Stock since the announcement: +22%.

📚 Go deeper: Faro Library reports

PDF reports built from official filings. Your first one is free, no email; then $1.99 each or all 33 for $25 — included in Navigator and Admiral.

See all 33 reports →

❓ Frequently asked questions about REGN

Could REGN be the next NVIDIA?

Its Faro multibagger DNA is 63/100 (promising): it measures how much it looks today like the big multibaggers did when they started (size, sales growth, quality, cash, price versus growth, balance sheet and public contracts). To grow ×10 it would need to be worth about 10 times today's value. Not a prediction or a recommendation.

How much has REGN gone up in the last year?

Regeneron Pharmaceuticals (REGN) is up 47.0% over the last 12 months and trades at $961.26, practically at its 52-week high. 52-week range: $600.66 – $961.26.

How volatile is REGN stock?

Its annualized volatility is around 36% and its worst drop from a peak over the last year was 26.1%. For reference, the S&P 500 usually moves 15–20% a year.

Does REGN have U.S. government contracts?

Yes. Faro's register lists 1 contract; the most recent: Health & Human Services, $278 M, Sep 25, 2026.

Is now a good time to buy REGN?

Nobody can know that for sure and this page is not a buy recommendation. What the data shows today: strongly bullish technical bias, RSI 88 (overbought zone), price above its 50-day average and an estimated 65% probability of being higher in 1 month. Use it as a starting point for research, not as a signal.

🧠 How it is calculated

The verdict combines trend (20/50/200 moving averages), momentum (RSI, MACD), mean reversion (Bollinger Bands), conviction (volume) and historical drift, weighted differently for each horizon. Uncertainty is modeled with a lognormal probability cone (geometric Brownian motion). This is statistical analysis, not a crystal ball.

🔦 Keep analyzing

Other stocks Faro watches

🔮 Oracle Pro 📈 Trading Room 📅 Calendar

⚠️ Educational tool. Not financial advice. Forecasts are statistical estimates based on historical volatility; the market can do the opposite. Data via Yahoo Finance. Always verify before trading. The decisions are yours.